North Carolina emerges as leader in world vaccine development
Related Blog Posts
- Agbio a fast-growing sector in N.C.'s life science industry
- Opinion: Pharma follows as the CROs fly
- N.C. Science and Math student a hit at BIO conference
- Who is hiring? N.C. life science employment up 7% since recession
- New Jersey firm buying Gentris for $4.75M; founder to return
- $1.8M federal grant helps N.C. land $200 million biofuel plant
On The Web
RESEARCH TRIANGLE PARK, N.C. - Blame it on today’s globe-hopping lifestyle.
Travelers are increasingly bringing what once were considered third-world diseases -- dengue fever and chikungunya, for example -- to backyards near you.
Fortunately, one American hot spot is leading the world in vaccine technologies. The next time you catch some scary news about unusual outbreaks, flu deaths, pandemics or bioterrorism, you can consider North Carolina your best hope for health.
North Carolina is the world vaccine leader. This top-tier bioscience state goes viral when vaccines are the topic.
For example, if dengue, chikungunya, West Nile and about 200 other mosquito-carried viruses have you concerned, Raleigh-based Arbovax has a platform for that (see blue box sidebar, right side of this story). The clinical–stage vaccine developer is connecting with investors to make dengue its first target. From there, the sky’s the limit.
North Carolina is also home to two of the world’s most advanced vaccine manufacturing factories, built in part by the federal government to be first responders when bad bugs hit.
Vaccines from the billion-dollar Novartis cell culture facility in Holly Springs are one example. That factory's egg-free Flucelvax flu vaccine, produced without antibiotics or preservatives, was just approved by the U.S. Food and Drug Administration. A year earlier, the FDA approved U.S. sales of Flucelvax produced at a similar Novartis factory in Marburg, Germany.
N.C.'s Life Science Industry: An Overview
Nearby, Medicago’s RTP vaccine factory is part greenhouse. It grows viral-like particles in tobacco leaves. Fast. It aced a test for the federal government by producing 10 million doses of flu vaccine in one month.
In all, N.C. has 28 vaccine companies employing 13,000 people in development and/or manufacturing. A big reason it’s such a vax magnet is its renowned workforce training. It includes biomanufacturing “classrooms” with industry-standard stainless steel vats and piping and custom-designed curricula that even the FDA uses to teach its own inspectors.
The state’s awesome vax pack includes big firms like Biogen Idec, Fujifilm Diosynth, DSM, GlaxoSmithKline, Greer Laboratories, Grifols, Merck, Pfizer and Zoetis.
And there’s a wide range of nimble, smaller players with fascinating technologies like the Arbovax platform, to tackle not only viral infections but cancer as well. Companies like Argos Therapeutics, Heat Biologics, Pique Therapeutics and Soy Meds.
North Carolina’s vaccine prowess is on display at the North Carolina Pavilion at the BIO International Convention through June 26 in San Diego.
Note: Jim Shamp is director of public relations for the Biotech Center.
(C) N.C. Biotechnology Center
Please Log In to add a comment.
Best of TechWire Insider
- N.C. Senate gives tentative OK to bill including crowdfunding
- Crowdfunding bill moves - again - as part of different legislation
- AT&T already seeking permits for rollout of ultrafast network
- Latest stats show institutional venture capital in N.C. becoming a joke
- With cities on board, N.C. Next Generation Network is rolling toward first big deployment target
- Is IBM-Apple deal a slap in the face for Lenovo?
- A rare look into economic recruitment, requirements: Cary's disappearing 1,237 jobs document
- N.C. Senate committee to consider crowdfunding bill
- NCTA renames its '21 Awards,' to honor winners with 'Beacon'
- Vivek Wadhwa's book 'Innovating Women' hits markets Sept. 2